Forbes' Matthew Herper notes that the CEO of Fougera, which Novartis is buying for $1.525B, is...

|By:, SA News Editor

Forbes' Matthew Herper notes that the CEO of Fougera, which Novartis is buying for $1.525B, is Brian Markison, who was CEO of King Pharmaceuticals when it was sold to Pfizer for $3.6B in 2010. Herper speculates that Markison won't be short of job offers, especially if there are any other drug firms looking to get bought.